Skip to main content
Top
Published in: Current Infectious Disease Reports 2/2017

01-02-2017 | Neurological Infections (J Lyons, Section Editor)

The Viral Connection to Glioblastoma

Authors: J. Ricardo McFaline-Figueroa, Patrick Y. Wen

Published in: Current Infectious Disease Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

The high incidence of and mortality from glioblastoma are matched by a lack of effective therapies. Previous research suggests an association between viral infection and glioma formation. In this manuscript, we review the available evidence for this association and the efficacy of treatment strategies targeted against viral infection.

Recent Findings

We find that while a wide array of viruses can drive glioma tumor formation in vitro and in xenograft models, the most convincing association is with the human Cytomegalovirus (HCMV). Detection of HCMV in glioblastoma resected from living patients suggests it may either drive gliomagenesis, support tumor growth, or reactivate silently in these tumors. However, there is conflicting evidence on its ubiquity and its role in tumor formation. Valganciclovir may extend survival in glioblastoma patients, though adequate data on its efficacy and mechanism of action are lacking. Immunotherapy provides the opportunity to specifically target the virus and possibly, glioblastoma, though there are no large, randomized trials testing its efficacy to date.

Summary

Overall, despite mounting evidence for an association between HCMV and glioblastoma, its role as an oncogenic factor and a therapeutic target remains controversial.
Literature
1.
go back to reference Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17 Suppl 4:iv1–62.CrossRefPubMedPubMedCentral Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology. 2015;17 Suppl 4:iv1–62.CrossRefPubMedPubMedCentral
2.
go back to reference Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.CrossRefPubMedPubMedCentral Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.CrossRefPubMedPubMedCentral
3.
go back to reference Shein HM. Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus. Science. 1968;159:1476–7.CrossRefPubMed Shein HM. Neoplastic transformation of hamster astrocytes in vitro by simian virus 40 and polyoma virus. Science. 1968;159:1476–7.CrossRefPubMed
4.
go back to reference Rabotti GF, Anderson WR, Sellers RL. Oncogenic activity of Mill Hill (Harris) strain of Rous sarcoma virus for hamsters. Nature. 1965;206:946–7.CrossRefPubMed Rabotti GF, Anderson WR, Sellers RL. Oncogenic activity of Mill Hill (Harris) strain of Rous sarcoma virus for hamsters. Nature. 1965;206:946–7.CrossRefPubMed
5.
go back to reference Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. Cancer Res. 1969;29:1173–8.PubMed Rapp F, Pauluzzi S, Waltz TA, Burdine JA, Matsen FA, Levy B. Induction of brain tumors in newborn hamsters by simian adenovirus SA7. Cancer Res. 1969;29:1173–8.PubMed
6.
go back to reference Yung WK, Blank NK, Vick NA. “Glioblastoma”. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology. 1976;26:76–83.CrossRefPubMed Yung WK, Blank NK, Vick NA. “Glioblastoma”. Induction of a reproducible autochonous tumor in rats with murine sarcoma virus. Neurology. 1976;26:76–83.CrossRefPubMed
7.••
go back to reference Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–50. This study first detected human cytomegalovirus DNA, RNA and proteins in human glioblastoma post-surgical samples.PubMed Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–50. This study first detected human cytomegalovirus DNA, RNA and proteins in human glioblastoma post-surgical samples.PubMed
8.
go back to reference Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10:10–8.CrossRefPubMedPubMedCentral Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10:10–8.CrossRefPubMedPubMedCentral
9.
go back to reference Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.CrossRefPubMed Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. The detection of CMV pp 65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103:231–8.CrossRefPubMed
10.
go back to reference Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–43.CrossRefPubMed Lau SK, Chen Y-Y, Chen W-G, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–43.CrossRefPubMed
11.
go back to reference Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–9.CrossRefPubMed Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–9.CrossRefPubMed
12.
go back to reference Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci. 2015;22:326–30.CrossRefPubMed Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci. 2015;22:326–30.CrossRefPubMed
13.
go back to reference Lin C-TM, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016;11:32. BioMed Central.CrossRefPubMedPubMedCentral Lin C-TM, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls. Infect Agent Cancer. 2016;11:32. BioMed Central.CrossRefPubMedPubMedCentral
14.
go back to reference Scheurer ME, El-Zein R, Bondy ML, Harkins L, Cobbs CS. RE: “Lack of association of herpesviruses with brain tumors”. J Neurovirol. 2007;13:85. author reply 86–7.CrossRefPubMed Scheurer ME, El-Zein R, Bondy ML, Harkins L, Cobbs CS. RE: “Lack of association of herpesviruses with brain tumors”. J Neurovirol. 2007;13:85. author reply 86–7.CrossRefPubMed
15.
go back to reference Poland SD, Costello P, Dekaban GA, Rice GP. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis. 1990;162:1252–62.CrossRefPubMed Poland SD, Costello P, Dekaban GA, Rice GP. Cytomegalovirus in the brain: in vitro infection of human brain-derived cells. J Infect Dis. 1990;162:1252–62.CrossRefPubMed
16.
go back to reference Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol. 1986;67(Pt 12):2605–16.CrossRefPubMed Ogura T, Tanaka J, Kamiya S, Sato H, Ogura H, Hatano M. Human cytomegalovirus persistent infection in a human central nervous system cell line: production of a variant virus with different growth characteristics. J Gen Virol. 1986;67(Pt 12):2605–16.CrossRefPubMed
17.
18.•
go back to reference Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204–13. This small, exploratory, double-blind, randomized control trial showed no benefit to adjuvant valganciclovir in regards to tumor progression, overall survival or progression free survival at 6 months.CrossRefPubMed Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204–13. This small, exploratory, double-blind, randomized control trial showed no benefit to adjuvant valganciclovir in regards to tumor progression, overall survival or progression free survival at 6 months.CrossRefPubMed
19.•
go back to reference Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–6. This retrospective analysis of the VIGAS trial, as well as other, non-study patients receiving valganciclovir, suggests a survival benefit to receiving at least 6 months of adjuvant valganciclovir.CrossRefPubMed Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–6. This retrospective analysis of the VIGAS trial, as well as other, non-study patients receiving valganciclovir, suggests a survival benefit to receiving at least 6 months of adjuvant valganciclovir.CrossRefPubMed
20.
go back to reference Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology. 2014;16:166.CrossRefPubMed Weller M, Soffietti R, Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro-Oncology. 2014;16:166.CrossRefPubMed
21.
go back to reference Liu C-J, Hu Y-W. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135:250–1.CrossRefPubMed Liu C-J, Hu Y-W. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135:250–1.CrossRefPubMed
22.
go back to reference Söderberg-Nauclér C, Peredo I, Rahbar A, Hansson F, Nordlund A, Stragliotto G. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 2014;135:248–9.CrossRefPubMed Söderberg-Nauclér C, Peredo I, Rahbar A, Hansson F, Nordlund A, Stragliotto G. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. Int J Cancer. 2014;135:248–9.CrossRefPubMed
23.
go back to reference Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience. Mol Clin Oncol. 2016;4:154–8.PubMed Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: a single-institution experience. Mol Clin Oncol. 2016;4:154–8.PubMed
24.
go back to reference Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–55.CrossRefPubMedPubMedCentral Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121:4043–55.CrossRefPubMedPubMedCentral
25.
go back to reference Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066.CrossRefPubMed Hellstrand K, Martner A, Bergström T. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066.CrossRefPubMed
26.
go back to reference Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066–7.CrossRefPubMed Söderberg-Nauclér C, Peredo I, Stragliotto G. Valganciclovir in patients with glioblastoma. N Engl J Med. 2013;369:2066–7.CrossRefPubMed
27.
go back to reference Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol. 2001;154:161–5.CrossRefPubMed Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol. 2001;154:161–5.CrossRefPubMed
28.
go back to reference Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. OncoImmunology. 2015;4:e982391.CrossRefPubMedPubMedCentral Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, et al. Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. OncoImmunology. 2015;4:e982391.CrossRefPubMedPubMedCentral
29.
go back to reference Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–83.CrossRefPubMedPubMedCentral Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19:6473–83.CrossRefPubMedPubMedCentral
30.
go back to reference Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. Springer US.CrossRefPubMed Kast RE, Ramiro S, Lladó S, Toro S, Coveñas R, Muñoz M. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. J Neurooncol. 2016;126:425–31. Springer US.CrossRefPubMed
31.
32.•
go back to reference Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9. This small, double-blinded, randomized-control trial of vaccination with pp65-exposed dendritic cells (a HCMV antigen) after tetanus/diphteria toxin preconditioning showed increased progression-free survival and overall survival in glioblastoma patients.CrossRefPubMedPubMedCentral Mitchell DA, Batich KA, Gunn MD, Huang M-N, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9. This small, double-blinded, randomized-control trial of vaccination with pp65-exposed dendritic cells (a HCMV antigen) after tetanus/diphteria toxin preconditioning showed increased progression-free survival and overall survival in glioblastoma patients.CrossRefPubMedPubMedCentral
34.
go back to reference Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012;90:872–80.CrossRefPubMed Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol. 2012;90:872–80.CrossRefPubMed
35.
go back to reference Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466–76.CrossRefPubMed Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466–76.CrossRefPubMed
Metadata
Title
The Viral Connection to Glioblastoma
Authors
J. Ricardo McFaline-Figueroa
Patrick Y. Wen
Publication date
01-02-2017
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 2/2017
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-017-0563-z

Other articles of this Issue 2/2017

Current Infectious Disease Reports 2/2017 Go to the issue

Neurological Infections (J Lyons, Section Editor)

Infectious Complications of Novel Multiple Sclerosis Therapies

Cardiovascular Infections (B Hoen, Section Editor)

Antibiotic Prophylaxis of Infective Endocarditis

Neurological Infections (J Lyons, Section Editor)

Neurologic Manifestation of Chikungunya Virus

Cardiovascular Infections (B Hoen, Section Editor)

Cardiac Imaging of Infective Endocarditis, Echo and Beyond

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.